368 related articles for article (PubMed ID: 23787155)
21. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study.
Provenzano R; Besarab A; Macdougall IC; Ellison DH; Maxwell AP; Sulowicz W; Klinger M; Rutkowski B; Correa-Rotter R; Dougherty FC;
Clin Nephrol; 2007 May; 67(5):306-17. PubMed ID: 17542340
[TBL] [Abstract][Full Text] [Related]
22. C.E.R.A. once every 4 weeks in patients with chronic kidney disease not on dialysis: The ARCTOS extension study.
Kessler M; Martínez-Castelao A; Siamopoulos KC; Villa G; Spinowitz B; Dougherty FC; Beyer U
Hemodial Int; 2010 Apr; 14(2):233-9. PubMed ID: 19888948
[TBL] [Abstract][Full Text] [Related]
23. Effects of erythropoietin on left ventricular hypertrophy in adults with severe chronic renal failure and hemoglobin <10 g/dL.
Ayus JC; Go AS; Valderrabano F; Verde E; de Vinuesa SG; Achinger SG; Lorenzo V; Arieff AI; Luño J;
Kidney Int; 2005 Aug; 68(2):788-95. PubMed ID: 16014057
[TBL] [Abstract][Full Text] [Related]
24. Effect of achieved hemoglobin level on renal outcome in non-dialysis chronic kidney disease (CKD) patients receiving epoetin beta pegol: MIRcerA CLinical Evidence on Renal Survival in CKD patients with renal anemia (MIRACLE-CKD Study).
Hayashi T; Uemura Y; Kumagai M; Kimpara M; Kanno H; Ohashi Y;
Clin Exp Nephrol; 2019 Mar; 23(3):349-361. PubMed ID: 30291472
[TBL] [Abstract][Full Text] [Related]
25. Maintaining high hemoglobin levels improved the left ventricular mass index and quality of life scores in pre-dialysis Japanese chronic kidney disease patients.
Hirakata H; Tsubakihara Y; Gejyo F; Nishi S; Iino Y; Watanabe Y; Suzuki M; Saito A; Akiba T; Inaguma D; Fukuhara S; Morita S; Hiroe M; Hada Y; Suzuki M; Akaishi M; Aonuma K; Akizawa T
Clin Exp Nephrol; 2010 Feb; 14(1):28-35. PubMed ID: 19763743
[TBL] [Abstract][Full Text] [Related]
26. Impact of anemia treatment for left ventricular hypertrophy using long-acting erythropoietin-stimulating agents from the pre-dialysis to maintenance dialysis period in patients with chronic kidney disease, retrospective longitudinal cohort study.
Io H; Muto M; Sasaki Y; Ishizaka M; Kano T; Fukuzaki H; Maeda T; Shimizu Y; Nakata J; Suzuki Y
BMC Nephrol; 2023 Mar; 24(1):74. PubMed ID: 36966289
[TBL] [Abstract][Full Text] [Related]
27. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency.
Toblli JE; Lombraña A; Duarte P; Di Gennaro F
J Am Coll Cardiol; 2007 Oct; 50(17):1657-65. PubMed ID: 17950147
[TBL] [Abstract][Full Text] [Related]
28. Time-averaged hemoglobin values, not hemoglobin cycling, have an impact on outcomes in pediatric dialysis patients.
Bakkaloğlu SA; Kandur Y; Serdaroğlu E; Noyan A; Bayazıt AK; Taşdemir M; Özlü SG; Özçelik G; Dursun İ; Alparslan C; Akcaboy M; Atikel YÖ; Parmaksız G; Atmış B; Sever L
Pediatr Nephrol; 2018 Nov; 33(11):2143-2150. PubMed ID: 30105415
[TBL] [Abstract][Full Text] [Related]
29. Erythropoietin therapy and left ventricular mass index in CKD and ESRD patients: a meta-analysis.
Parfrey PS; Lauve M; Latremouille-Viau D; Lefebvre P
Clin J Am Soc Nephrol; 2009 Apr; 4(4):755-62. PubMed ID: 19339417
[TBL] [Abstract][Full Text] [Related]
30. [Left ventricular hypertrophy in patients on hemodialysis: importance of anemia].
Stojimirović B; Petrović D; Obrenović R
Med Pregl; 2007; 60 Suppl 2():155-9. PubMed ID: 18928184
[TBL] [Abstract][Full Text] [Related]
31. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.
Sulowicz W; Locatelli F; Ryckelynck JP; Balla J; Csiky B; Harris K; Ehrhard P; Beyer U;
Clin J Am Soc Nephrol; 2007 Jul; 2(4):637-46. PubMed ID: 17699476
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial.
Klinger M; Arias M; Vargemezis V; Besarab A; Sulowicz W; Gerntholtz T; Ciechanowski K; Dougherty FC; Beyer U
Am J Kidney Dis; 2007 Dec; 50(6):989-1000. PubMed ID: 18037099
[TBL] [Abstract][Full Text] [Related]
33. Erythropoiesis-stimulating agents, hypertension and left ventricular hypertrophy in the chronic kidney disease patient.
Schmid H; Schiffl H; Lederer SR
Curr Opin Nephrol Hypertens; 2011 Sep; 20(5):465-70. PubMed ID: 21738032
[TBL] [Abstract][Full Text] [Related]
34. High target hemoglobin with erythropoiesis-stimulating agents has advantages in the renal function of non-dialysis chronic kidney disease patients.
Tsubakihara Y; Gejyo F; Nishi S; Iino Y; Watanabe Y; Suzuki M; Saito A; Akiba T; Hirakata H; Akizawa T
Ther Apher Dial; 2012 Dec; 16(6):529-40. PubMed ID: 23190512
[TBL] [Abstract][Full Text] [Related]
35. An open-label study of darbepoetin alfa administered once monthly for the maintenance of haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis.
Agarwal AK; Silver MR; Reed JE; Dhingra RK; Liu W; Varma N; Stehman-Breen C
J Intern Med; 2006 Dec; 260(6):577-85. PubMed ID: 17116009
[TBL] [Abstract][Full Text] [Related]
36. Effect of erythropoietin on cardiovascular prognosis parameters in hemodialysis patients.
Frank H; Heusser K; Höffken B; Huber P; Schmieder RE; Schobel HP
Kidney Int; 2004 Aug; 66(2):832-40. PubMed ID: 15253740
[TBL] [Abstract][Full Text] [Related]
37. Effects of optimized heart failure therapy and anemia correction with epoetin beta on left ventricular mass in hemodialysis patients.
Hampl H; Hennig L; Rosenberger C; Amirkhalily M; Gogoll L; Riedel E; Scherhag A
Am J Nephrol; 2005; 25(3):211-20. PubMed ID: 15900093
[TBL] [Abstract][Full Text] [Related]
38. Predictive factors associated with change rates of LV hypertrophy and renal dysfunction in CKD patients.
Okumura K; Io H; Matsumoto M; Seto T; Takagi M; Masuda A; Furukawa M; Nagahama L; Omote K; Hisada A; Hamada C; Horikoshi S; Tomino Y
Clin Nephrol; 2013 Jan; 79(1):7-14. PubMed ID: 23036229
[TBL] [Abstract][Full Text] [Related]
39. Renormalization of high cardiac output and of left ventricular size following long-term recombinant human erythropoietin treatment of anemic dialyzed uremic patients.
Cannella G; La Canna G; Sandrini M; Gaggiotti M; Nordio G; Movilli E; Maiorca R
Clin Nephrol; 1990 Dec; 34(6):272-8. PubMed ID: 2073771
[TBL] [Abstract][Full Text] [Related]
40. Hemoglobin levels, cardiovascular disease, and left ventricular hypertrophy in patients with chronic kidney disease. Case study of the anemic patient.
Butler KG
Nephrol Nurs J; 2002 Apr; 29(2):189-92. PubMed ID: 11997954
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
